Q2 H1

• Net sales reached SEK 8.8 (9.6) · Net sales reached SEK 21.8 (13.8)

million. million.

• The operating result totaled SEK · The operating result totaled SEK

-11.2 (-15.9) million. -25.5 (-34.0) million.

• Earnings per share, basic and · Earnings per share, basic and

diluted, were SEK -0.07 (-0.10). diluted, were SEK -0.16 (-0.22).

• Cash flow from operating · Cash flow from operating

activities totaled SEK -9.5 (-21.5) activities totaled SEK -21.7 (-31.7)
million. million.

Significant events during the Significant events after the quarter
quarter

• No significant events · No significant events were reported after

were reported during the the end of the quarter.
quarter.
Other events during and after
the quarter

• The University of Kent,

UK, conducted a clinical
study starting in November
2022 to investigate
ColdZyme's effects in-vivo
among elite athletes in
endurance sports such as
cycling and long-distance
running. The results of the
placebo-controlled, double
-blind, and randomized study
are expected in August 2023.

• The Medical University of

Innsbruck, Austria, conducted
an in vitro study during the
second quarter to explore the
effect of ColdZyme on human
cells infected with influenza
virus. The study results are
expected in August 2023.

"The first half of 2023 showed 58% growth compared to the same period last year. The second quarter is always the weakest of the year for us, as it is the period when the number of colds is the lowest. Still, the second quarter was an intense period. Discussions on launches in some of the world's largest cold markets intensified and our research program continued. In August, we expect the results from two important scientific studies", said Claus Egstrand, CEO of Enzymatica.

The full report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on July 18, 2023.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com

Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank.